Jane Street Group LLC Purchases New Position in NeoGenomics, Inc. (NEO)

Jane Street Group LLC purchased a new position in NeoGenomics, Inc. (NASDAQ:NEO) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 348,184 shares of the medical research company’s stock, valued at approximately $4,391,000. Jane Street Group LLC owned about 0.37% of NeoGenomics as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of NEO. Victory Capital Management Inc. acquired a new stake in shares of NeoGenomics during the 3rd quarter valued at $2,979,000. American Century Companies Inc. bought a new stake in NeoGenomics during the third quarter valued at about $4,724,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in NeoGenomics during the third quarter valued at about $763,000. JPMorgan Chase & Co. lifted its stake in shares of NeoGenomics by 423.8% in the third quarter. JPMorgan Chase & Co. now owns 60,259 shares of the medical research company’s stock valued at $925,000 after buying an additional 48,754 shares during the period. Finally, Prudential Financial Inc. bought a new stake in shares of NeoGenomics in the third quarter valued at about $224,000. Institutional investors own 77.24% of the company’s stock.

Shares of NeoGenomics stock traded down $0.24 during midday trading on Monday, reaching $21.56. The company had a trading volume of 801,689 shares, compared to its average volume of 1,240,620. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.70 and a quick ratio of 1.56. The firm has a market cap of $2.06 billion, a P/E ratio of 165.85 and a beta of 0.93. NeoGenomics, Inc. has a 1-year low of $8.95 and a 1-year high of $22.17.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, February 19th. The medical research company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. NeoGenomics had a net margin of 0.95% and a return on equity of 2.25%. The firm had revenue of $76.50 million during the quarter, compared to analyst estimates of $71.29 million. During the same quarter in the previous year, the business earned $0.05 EPS. The business’s quarterly revenue was up 24.6% compared to the same quarter last year. On average, sell-side analysts expect that NeoGenomics, Inc. will post 0.18 EPS for the current year.

In other NeoGenomics news, VP Jennifer Balliet sold 14,000 shares of NeoGenomics stock in a transaction on Monday, March 4th. The shares were sold at an average price of $19.09, for a total transaction of $267,260.00. Following the completion of the sale, the vice president now owns 40,000 shares of the company’s stock, valued at approximately $763,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Steven C. Jones sold 14,621 shares of NeoGenomics stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $19.24, for a total transaction of $281,308.04. Following the sale, the executive vice president now directly owns 241,815 shares of the company’s stock, valued at approximately $4,652,520.60. The disclosure for this sale can be found here. Insiders have sold a total of 263,524 shares of company stock valued at $5,019,496 in the last ninety days. Company insiders own 12.20% of the company’s stock.

Several analysts have recently weighed in on the stock. Needham & Company LLC raised their price objective on shares of NeoGenomics from $19.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, March 29th. CIBC raised shares of NeoGenomics from a “neutral” rating to an “outperform” rating and dropped their price objective for the stock from $18.00 to $15.00 in a report on Tuesday, March 12th. Zacks Investment Research raised shares of NeoGenomics from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a report on Tuesday, March 5th. BidaskClub raised shares of NeoGenomics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 20th. Finally, ValuEngine raised shares of NeoGenomics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 10th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. NeoGenomics has a consensus rating of “Buy” and an average price target of $19.55.

TRADEMARK VIOLATION WARNING: This piece was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/04/15/jane-street-group-llc-buys-shares-of-348184-neogenomics-inc-neo.html.

NeoGenomics Company Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

See Also: How to interpret the current ratio

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.